Palisade Bio (PALI)

Company Profile

Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

Company profile

Ticker

PALI

Exchange

NASDAQ

Website

www.palisadebio.com

CEO

Kenneth Carter

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...

Former names

Neuralstem, Inc., Seneca Biopharma, Inc.

SEC CIK

0001357459

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Leading Biosciences, Inc. • Suzhou Neuralstem Biopharmaceutical Co., Ltd. ...

IRS number

522007292

PALI stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution

8 Feb 23

EFFECT

Notice of effectiveness

25 Jan 23

424B3

Prospectus supplement

24 Jan 23

CORRESP

Correspondence with SEC

$2.50 mm in options / securities to be acquired, sold $2.50 mm, 6 investors

Entry into a Material Definitive Agreement

4 Jan 23

424B5

Prospectus supplement for primary offering

4 Jan 23

Latest ownership filings

View all

Robert Curtis McRae

15 Feb 23

SC 13G

ARMISTICE CAPITAL, LLC

14 Feb 23

SC 13G/A

Altium Capital Management LP

14 Feb 23

SC 13G/A

Lind Global Fund II LP

INTRACOASTAL CAPITAL, LLC

INTRACOASTAL CAPITAL, LLC

22 Aug 22

Financial summary

Financial statements Chart PALI financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	14.01 mm	14.01 mm	14.01 mm	14.01 mm	14.01 mm	14.01 mm
Cash burn (monthly)	(no burn)	9.92 k	1.47 mm	1.33 mm	1.01 mm	1.09 mm
Cash used (since last report)	n/a	56.45 k	8.37 mm	7.54 mm	5.77 mm	6.22 mm
Cash remaining	n/a	13.95 mm	5.64 mm	6.47 mm	8.24 mm	7.79 mm
Runway (months of cash)	n/a	1407.2	3.8	4.9	8.1	7.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

PALI institutional ownership history Ownership history

6.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	16	35	-54.3%
Opened positions	3	10	-70.0%
Closed positions	22	3	+633.3%
Increased positions	0	9	EXIT
Reduced positions	12	2	+500.0%

13F shares	Current	Prev Q	Change
Total value	541.64 mm	8.80 mm	+6057.1%
Total shares	2.82 mm	22.22 mm	-87.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Regional Medical Center Yuma	2.25 mm	$5.55 mm	0.0%
Armistice Capital	281.05 k	$0.00	NEW
Intracoastal Capital	131.09 k	$0.00	-98.3%
CVI	40.00 k	$208.00 mm	NEW
Lind Global Fund II	30.99 k	$0.00	-99.2%
Warberg Asset Management	26.32 k	$136.84 mm	-82.5%
Virtu Financial	20.46 k	$106.00 k	-81.3%
Two Sigma Securities	19.69 k	$102.40 mm	-75.9%
Two Sigma Investments	10.40 k	$54.06 mm	-87.1%
UBS UBS Group AG - Registered Shares	4.12 k	$21.40 mm	-95.9%

Largest transactions	Shares	Bought/sold	Change
Intracoastal Capital	131.09 k	-7.47 mm	-98.3%
Altium Capital Management	0.00	-5.64 mm	EXIT
Lind Global Fund II	30.99 k	-3.97 mm	-99.2%
Sargent Investment	0.00	-670.00 k	EXIT
Renaissance Technologies	0.00	-512.07 k	EXIT
Sabby Management	0.00	-445.90 k	EXIT
Armistice Capital	281.05 k	+281.05 k	NEW
Geode Capital Management	0.00	-130.02 k	EXIT
Warberg Asset Management	26.32 k	-123.68 k	-82.5%
UBS UBS Group AG - Registered Shares	4.12 k	-96.52 k	-95.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PALI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Feb 23	John David Finley	Common Stock	Grant	Acquire A	No	No	2.4	57,200	137.28 k	57,200
6 Feb 23	John David Finley	Common Stock	Grant	Acquire A	No	No	0	32,500	0.00	32,500
6 Feb 23	John David Finley	Common Stock	Grant	Acquire A	No	No	0	41,700	0.00	41,700
3 Jan 23	John David Finley	Common Stock	Grant	Acquire A	No	No	0	5,236	0.00	5,236
1 Sep 22	John David Finley	Common Stock, par value $0.01	Buy	Acquire P	No	No	0.1437	19,481.242	2.80 k	148,727.242
23 Aug 22	John David Finley	Common Stock, par value $0.01	Buy	Acquire P	No	No	0.16	7,350	1.18 k	129,246